Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of the
investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug,
PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic
(numbing) spray containing a mixture of lidocaine and prilocaine. The study drug will be
applied in a spray to the penis prior to intercourse in order to decrease sensitivity in an
attempt to delay ejaculation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Plethora Solutions Ltd
Collaborator:
Shionogi Inc.
Treatments:
Anesthetics EMLA Lidocaine Lidocaine, Prilocaine Drug Combination Prilocaine